<DOC>
	<DOC>NCT01478893</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and pharmacodynamics of SEL-068. Increasing subcutaneous doses of SEL-068 will be administered to healthy non-smoker and smoker volunteers. The resulting safety profile and anti-nicotine antibody levels will be evaluated.</brief_summary>
	<brief_title>Safety and Pharmacodynamics of SEL-068 Vaccine in Smokers and Non-Smokers</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Primary Healthy Smokers Healthy nonsmokers Written informed consent Primary Prior exposure to nicotine vaccines Female subjects of childbearing potential Current use of immunosuppressive agents History of or current autoimmune disorder of immunosuppressive condition (e.g. HIV infection) Concurrent participation or participation within 8 weeks prior to the initial study drug administration in a drug/device or biologic investigational research study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>nicotine vaccine</keyword>
	<keyword>smoking vaccine</keyword>
	<keyword>smoking cessation</keyword>
	<keyword>SEL-068</keyword>
</DOC>